With Spravato Buy and Bill, the practice purchases the medication through an authorized distribution channel, administers it to an eligible patient, bills the appropriate payer, and collects reimbursement after treatment is complete.
The basic flow looks like this:
Payer Verification, then Prior Authorization, then Drug Acquisition, then Treatment, then Claim Submission, then Payment, then Reconciliation.
This model gives practices more control over both the medication and the reimbursement process, but it also comes with real financial risk. Buy the drug before coverage is confirmed, and a denial or underpayment leaves the practice holding the cost, not the payer.
That’s the core principle worth building around: Spravato Buy and Bill should start with reimbursement, not with inventory.
Before purchasing SPRAVATO, your healthcare setting has to meet the applicable SPRAVATO REMS requirements. The manufacturer currently identifies authorized distribution channels for certified healthcare settings, including specialty distributors used by some outpatient treatment centers running Buy and Bill programs.
Don’t pick a distributor based on convenience alone. Compare acquisition price, payment terms, ordering requirements, delivery process, credit availability, and account setup requirements across your options.
Even small differences in acquisition cost can meaningfully affect margin once treatment volume picks up.
This is one of the most important steps in the entire process, and it’s an easy one to get wrong.
Don’t assume that because one payer reimburses Spravato through Buy and Bill, another payer will do the same. Before treatment, verify whether Spravato is covered at all, whether it falls under the medical or pharmacy benefit, whether Buy and Bill is even permitted, whether specialty pharmacy is required instead, whether Prior Authorization applies, which provider and location need to be authorized, and what reimbursement to actually expect.
A patient can have active insurance and still be on a plan that doesn’t support the acquisition pathway you’re planning to use. Our Spravato Billing Services are built specifically to sort this out before the medication is ever purchased.
A profitable Buy and Bill program comes down to a fairly simple equation: expected collected reimbursement, minus drug acquisition cost, minus treatment and administrative costs, equals expected margin.
What matters isn’t what you charge. It’s what the payer actually allows and ultimately pays out.
Practices should review reimbursement payer by payer rather than relying on one blended average across the entire patient population. If a particular payer consistently reimburses below expectations, pays slowly, or requires a different drug pathway altogether, that needs to surface before volume scales up, not after.
Prior Authorization matters so much here because the practice is already financially exposed the moment medication is purchased and treatment is delivered.
Authorization should be checked against approved dose, treatment frequency, effective dates, authorized provider, treatment location, required clinical documentation, and reauthorization requirements.
The administrative load behind all of this is significant across healthcare generally. The AMA’s 2025 survey found that physicians and their staff handle roughly 40 Prior Authorizations per physician each week, taking up around 13 hours of time. For Spravato specifically, weak authorization management can turn into a revenue problem fast.
Buy and Bill demands disciplined inventory control. The SPRAVATO REMS requires certified healthcare settings to keep records of shipments received and dispensing details, including the patient, dose, number of devices, and administration date.
From a revenue standpoint, your internal records should also connect the full chain: medication received, medication administered, patient treated, claim submitted, payment received.
That connection is what lets a practice catch missing claims, inventory discrepancies, billing mistakes, and unpaid treatments. If medication leaves inventory and there’s no matching reimbursement to show for it, that should trigger an immediate review.
Submitting the claim isn’t the finish line for Buy and Bill. Every payment needs to be checked against what the practice actually expected to receive.
Watch for incorrect drug units, denied medication lines, authorization mismatches, unexpected payer reductions, underpayments, unpaid claims, and repeated payer-specific issues.
A claim marked “paid” isn’t automatically paid correctly. This is one of the biggest, quietest ways practices lose Spravato revenue without ever noticing.
The problems we see most often aren’t complicated. They tend to be:
A well-built Spravato Buy and Bill workflow catches these issues before they ever turn into write-offs.
As a leading Spravato Billing Services Company, Finnastra focuses on protecting the revenue behind every treatment, not just getting claims out the door.
We help practices verify payer Buy and Bill requirements, manage eligibility and Prior Authorization, compare acquisition and reimbursement economics, align authorization with billing, review coding and claim accuracy, reconcile treatment activity with payments, identify denials and underpayments, and follow AR through to final resolution.
Working with a dedicated Spravato Billing Company like Finnastra isn’t just about getting claims submitted. It’s about making sure the entire financial workflow actually makes sense before the medication is ever purchased.
1. Is Buy and Bill available for every Spravato patient?
No. The right medication pathway can vary by payer and plan, so benefits need to be verified before treatment begins.
2. Is Spravato Buy and Bill profitable?
It can be. Profitability comes down to acquisition cost, payer reimbursement, authorization accuracy, payment timing, and operational expenses.
3. Should we buy medication before Prior Authorization is confirmed?
For insured patients, coverage and authorization requirements should be confirmed first, before the practice takes on unnecessary financial exposure.
4. Can Finnastra help set up Spravato Buy and Bill?
Yes. Finnastra supports payer verification, Prior Authorization, acquisition planning, billing, payment reconciliation, denials, underpayments, and AR.
Spravato Buy and Bill can give psychiatry practices real control over treatment operations and reimbursement, but only when drug acquisition, payer verification, authorization, claims, inventory, and collections all work together as one connected process.
Practices searching for a Top Spravato Billing Company in the U.S., or the Best Spravato Billing Company in the U.S., should look for a partner that understands the economics behind the medication itself, not just a vendor that submits claims.
Finnastra helps practices build that workflow from payer verification all the way through final reimbursement.
